Hong Kong: These 33 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

Generic name: pirfenidone
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: September 22, 2026
Generic Entry Controlled by: Hong Kong Patent 1,117,762

ESBRIET is a drug marketed by Legacy Pharma. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has two hundred and sixty-six patent family members in forty-six countries. There has been litigation on patents covering ESBRIET

See drug price trends for ESBRIET.

The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.

Generic name: lefamulin acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 20, 2027
Generic Entry Controlled by: Hong Kong Patent 1,140,185

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug.

This drug has one hundred and twenty patent family members in thirty-six countries. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. One supplier is listed for this generic product. Additional details are available on the lefamulin acetate profile page.

Generic name: deoxycholic acid
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2027
Generic Entry Controlled by: Hong Kong Patent 1,165,807

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.

Generic name: macitentan
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 29, 2026
Generic Entry Controlled by: Hong Kong Patent 1,133,597

OPSUMIT is a drug marketed by Actelion. There are five patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and one patent family members in thirty-five countries. There has been litigation on patents covering OPSUMIT

See drug price trends for OPSUMIT.

The generic ingredient in OPSUMIT is macitentan. There are ten drug master file entries for this API. Fourteen suppliers are listed for this generic product. Additional details are available on the macitentan profile page.

Generic name: ambrisentan
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 12, 2026
Generic Entry Controlled by: Hong Kong Patent 1,218,393

LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-one patent family members in twenty-six countries. There has been litigation on patents covering LETAIRIS

See drug price trends for LETAIRIS.

The generic ingredient in LETAIRIS is ambrisentan. There are nine drug master file entries for this API. Thirteen suppliers are listed for this generic product. Additional details are available on the ambrisentan profile page.

Generic name: bedaquiline fumarate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 05, 2026
Generic Entry Controlled by: Hong Kong Patent 1,214,513

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

This drug has ninety-seven patent family members in thirty-nine countries.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the bedaquiline fumarate profile page.

Generic name: tepotinib hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: Hong Kong Patent 1,142,891

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug.

This drug has eighty patent family members in thirty-seven countries. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tepotinib hydrochloride profile page.

Generic name: tepotinib hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: Hong Kong Patent 1,145,265

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug.

This drug has eighty patent family members in thirty-seven countries. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tepotinib hydrochloride profile page.

Generic name: prasterone
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 10, 2027
Generic Entry Controlled by: Hong Kong Patent 1,217,639

INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug.

This drug has fifty-nine patent family members in thirty-two countries. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the prasterone profile page.

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 01, 2027
Generic Entry Controlled by: Hong Kong Patent 1,138,188

OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug.

This drug has one hundred and one patent family members in forty-two countries. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are ten drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

Generic name: ruxolitinib phosphate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: Hong Kong Patent 1,143,161

JAKAFI is a drug marketed by Incyte Corp. There are twenty-five patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.

Generic name: ruxolitinib phosphate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: Hong Kong Patent 1,198,652

JAKAFI is a drug marketed by Incyte Corp. There are twenty-five patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.

Generic name: eltrombopag olamine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 03, 2027
Generic Entry Controlled by: Hong Kong Patent 1,136,968

PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.

Generic name: difelikefalin acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 10, 2026
Generic Entry Controlled by: Hong Kong Patent 1,130,814

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.

This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 15, 2026
Generic Entry Controlled by: Hong Kong Patent 1,119,559

CREON is a drug marketed by

See drug price trends for CREON.

The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

Generic name: sucroferric oxyhydroxide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 16, 2027
Generic Entry Controlled by: Hong Kong Patent 1,207,298

VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug.

This drug has one hundred and thirty-six patent family members in thirty-six countries. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. There are four drug master file entries for this API. Additional details are available on the sucroferric oxyhydroxide profile page.

Generic name: triptorelin pamoate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 06, 2027
Generic Entry Controlled by: Hong Kong Patent 1,141,737

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

This drug has forty-seven patent family members in thirty-two countries.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.

Generic name: remimazolam besylate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 10, 2027
Generic Entry Controlled by: Hong Kong Patent 1,137,739

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug.

This drug has fifty-three patent family members in twenty-four countries. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. One supplier is listed for this generic product. Additional details are available on the remimazolam besylate profile page.

Generic name: gallium ga-68 gozetotide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 17, 2027
Generic Entry Controlled by: Hong Kong Patent 1,212,588

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has fifty-five patent family members in sixteen countries.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. There are sixteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the gallium ga-68 gozetotide profile page.

Generic name: triptorelin pamoate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 06, 2027
Generic Entry Controlled by: Hong Kong Patent 1,141,737

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

This drug has forty-seven patent family members in thirty-two countries.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.

Generic name: diazoxide choline
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 20, 2026
Generic Entry Controlled by: Hong Kong Patent 1,117,078

VYKAT XR is a drug marketed by Soleno Therap. There are six patents protecting this drug.

This drug has seventy-nine patent family members in twenty-two countries.

The generic ingredient in VYKAT XR is diazoxide choline. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the diazoxide choline profile page.

Generic name: abaloparatide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 03, 2026
Generic Entry Controlled by: Hong Kong Patent 1,214,181

TYMLOS is a drug marketed by Radius. There are nine patents protecting this drug.

This drug has fifty-six patent family members in twenty-nine countries. There has been litigation on patents covering TYMLOS

See drug price trends for TYMLOS.

The generic ingredient in TYMLOS is abaloparatide. One supplier is listed for this generic product. Additional details are available on the abaloparatide profile page.

Generic name: quizartinib dihydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 16, 2027
Generic Entry Controlled by: Hong Kong Patent 1,131,141

VANFLYTA is a drug marketed by Daiichi Sankyo Inc. There are eleven patents protecting this drug.

This drug has one hundred and twenty-seven patent family members in thirty-three countries.

See drug price trends for VANFLYTA.

The generic ingredient in VANFLYTA is quizartinib dihydrochloride. One supplier is listed for this generic product. Additional details are available on the quizartinib dihydrochloride profile page.

Generic name: seladelpar lysine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: September 13, 2026
Generic Entry Controlled by: Hong Kong Patent 1,122,699

LIVDELZI is a drug marketed by Gilead Sciences Inc. There are six patents protecting this drug.

This drug has one hundred and thirty-eight patent family members in forty-six countries.

The generic ingredient in LIVDELZI is seladelpar lysine. One supplier is listed for this generic product. Additional details are available on the seladelpar lysine profile page.

Generic name: etripamil
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 20, 2027
Generic Entry Controlled by: Hong Kong Patent 1,140,913

CARDAMYST is a drug marketed by Milestone Pharms Usa. There are six patents protecting this drug.

This drug has sixty-six patent family members in twenty-nine countries. There has been litigation on patents covering CARDAMYST

See drug price trends for CARDAMYST.

The generic ingredient in CARDAMYST is etripamil. One supplier is listed for this generic product. Additional details are available on the etripamil profile page.

Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 31, 2026
Generic Entry Controlled by: Hong Kong Patent 1,086,277

INVOKAMET XR is a drug marketed by Janssen Pharms. There are three patents protecting this drug.

This drug has two hundred and twenty patent family members in forty-five countries. There has been litigation on patents covering INVOKAMET XR

See drug price trends for INVOKAMET XR.

The generic ingredient in INVOKAMET XR is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

Generic name: canagliflozin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 31, 2026
Generic Entry Controlled by: Hong Kong Patent 1,086,277

INVOKANA is a drug marketed by Janssen Pharms. There are three patents protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market.

This drug has two hundred and twenty patent family members in forty-five countries. There has been litigation on patents covering INVOKANA

See drug price trends for INVOKANA.

The generic ingredient in INVOKANA is canagliflozin. There are twenty-one drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the canagliflozin profile page.

Generic name: daclatasvir dihydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 09, 2027
Generic Entry Controlled by: Hong Kong Patent 1,126,486

DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug.

This drug has ninety-three patent family members in thirty-one countries. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. There are five drug master file entries for this API. Additional details are available on the daclatasvir dihydrochloride profile page.

Generic name: daclatasvir dihydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 11, 2026
Generic Entry Controlled by: Hong Kong Patent 1,201,535

DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug.

This drug has ninety-three patent family members in thirty-one countries. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. There are five drug master file entries for this API. Additional details are available on the daclatasvir dihydrochloride profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 07, 2027
Generic Entry Controlled by: Hong Kong Patent 1,146,819

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug.

This drug has four hundred and sixty-one patent family members in thirty-six countries. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: allopurinol; lesinurad
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 27, 2027
Generic Entry Controlled by: Hong Kong Patent 1,172,326

DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug.

This drug has one hundred and forty-four patent family members in thirty-nine countries. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. There are twenty-two drug master file entries for this API. Additional details are available on the allopurinol; lesinurad profile page.

Generic name: lesinurad
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 27, 2027
Generic Entry Controlled by: Hong Kong Patent 1,172,326

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug.

This drug has one hundred and forty-four patent family members in thirty-nine countries. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

Generic name: ceritinib
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 08, 2026
Generic Entry Controlled by: Hong Kong Patent 1,134,290

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

This drug has three hundred and twenty-two patent family members in fifty-six countries.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.

Generic name: paliperidone palmitate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 19, 2027
Generic Entry Controlled by: Hong Kong Patent 1,223,850

INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market.

This drug has thirty-eight patent family members in twenty-nine countries. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. There are thirty-eight drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the paliperidone palmitate profile page.

Generic name: betrixaban
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 07, 2026
Generic Entry Controlled by: Hong Kong Patent 1,115,131

BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug.

This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering BEVYXXA

See drug price trends for BEVYXXA.

The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.

Generic name: atazanavir sulfate; cobicistat
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 06, 2027
Generic Entry Controlled by: Hong Kong Patent 1,126,485

EVOTAZ is a drug marketed by Bristol. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and six patent family members in forty-one countries. There has been litigation on patents covering EVOTAZ

See drug price trends for EVOTAZ.

The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the atazanavir sulfate; cobicistat profile page.

Generic name: fedratinib hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 26, 2026
Generic Entry Controlled by: Hong Kong Patent 1,121,148

INREBIC is a drug marketed by Bristol-myers. There are five patents protecting this drug.

This drug has one hundred and nineteen patent family members in forty-two countries. There has been litigation on patents covering INREBIC

See drug price trends for INREBIC.

The generic ingredient in INREBIC is fedratinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the fedratinib hydrochloride profile page.

Generic name: piflufolastat f-18
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 08, 2026
Generic Entry Controlled by: Hong Kong Patent 1,200,164

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

This drug has one hundred and eighteen patent family members in twenty-seven countries.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. Two suppliers are listed for this generic product. Additional details are available on the piflufolastat f-18 profile page.

Generic name: piflufolastat f-18
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 08, 2026
Generic Entry Controlled by: Hong Kong Patent 1,257,260

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

This drug has one hundred and eighteen patent family members in twenty-seven countries.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. Two suppliers are listed for this generic product. Additional details are available on the piflufolastat f-18 profile page.

Generic name: piflufolastat f-18
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 08, 2026
Generic Entry Controlled by: Hong Kong Patent 1,200,164

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

This drug has one hundred and eighteen patent family members in twenty-seven countries.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Two suppliers are listed for this generic product. Additional details are available on the piflufolastat f-18 profile page.

Generic name: piflufolastat f-18
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 08, 2026
Generic Entry Controlled by: Hong Kong Patent 1,257,260

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

This drug has one hundred and eighteen patent family members in twenty-seven countries.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Two suppliers are listed for this generic product. Additional details are available on the piflufolastat f-18 profile page.

Generic name: cariprazine hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 11, 2027
Generic Entry Controlled by: Hong Kong Patent 1,140,473

VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug.

This drug has one hundred and twenty-one patent family members in forty-two countries. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cariprazine hydrochloride profile page.